
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes is a fully integrated biotechnology company focused on developing innovative treatments for unmet medical needs in various therapeutic areas. Their orexin program, specifically ALKS 7290 and ALKS 2680, shows promise in treating sleep disorders and could potentially lead to significant revenue growth. The company's commitment to exploring treatments for a range of conditions, including depression, schizophrenia, and cancer, demonstrates their dedication to improving patient quality of life and sets them apart in the biotechnology industry.
Bears say
Alkermes is a biopharmaceutical company with a negative outlook due to concerns about the commercial viability of its lead clinical candidate ALKS 2680, potential competition in the market for idiopathic hypersomnia treatments, and undervaluation of its orexin franchise. While ALKS 2680 could be a major opportunity for the company, there are concerns about its effectiveness and tolerability compared to current treatments. In addition, the potential for other companies to enter the market for idiopathic hypersomnia treatments could lead to increased competition and reduced market share for Alkermes. Furthermore, the company's orexin franchise, although potentially valuable, is not being appropriately valued in the market, and the base business is also undervalued.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares